Oral GLP-1 Candidate RV-8451 Targets Muscle Preservation in Obesity
Rivus Pharmaceuticals is bringing preclinical non-human primate obesity data for its oral GLP-1 candidate RV-8451 to Ob…
Rivus Pharmaceuticals is bringing preclinical non-human primate obesity data for its oral GLP-1 candidate RV-8451 to Ob…
Microbiotica's Series C financing signals growing investor confidence in orally dosed, precision microbiome therapeutic…
Seres Therapeutics is presenting preclinical data for SER-428, a novel oral liquid live biotherapeutic formulated for c…
Biomea Fusion reports Phase 1 data for BMF-650, an investigational oral GLP-1 receptor agonist showing sustained weight…
VIVUS's price reduction positions QSYMIA among the most accessible branded prescription weight-management therapies in …
iBio's IBIO-610 Activin E antibody demonstrated striking muscle-preservation data in obese non-human primates alongside…
Sironax's Phase 2 FORGE-LM trial is evaluating SIR4156 as a potential obesity treatment designed to promote fat loss wi…
Ozari Health's LegitScript-certified platform now offers compounded semaglutide with B12 and tirzepatide with B12 throu…
Clearmind Medicine's Japanese patent publication positions palmitoylethanolamide alongside a novel compound for neurolo…
Life Time's 30 Strong Challenge, returning for its third year with 66,000 participants in 2025, structures daily nutrit…
Bucked Up's Halloween limited-run extends across five pre-workout SKUs and its ready-to-drink energy can, with caffeine…
Grenade's U.S. entry targets a protein bar segment growing at four times the rate of total protein snacks, with distrib…